{
  "ticker": "BDX",
  "content": "**Report Generated:** January 16, 2026  \n**Next Refresh:** April 17, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Becton, Dickinson and Company (BDX) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nBecton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. For over 125 years, BD has been advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.\n\nBD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023. The company operates through three main business segments: BD Medical, BD Life Sciences, and BD Interventional. The company has a global presence across over 190 countries and relies on more than 34 billion devices delivered annually.\n\n## 2. Current Market Data\n\nBDX · Becton, Dickinson and Company · 203.61 · +2.35% Mkt Cap 58.114B · Industry Medical Instruments & Supplies\n\n**Current Stock Price**: The current price of BDX is 208.35 USD — it has increased by 2.93% in the past 24 hours.\n\n**Market Capitalization**: As of January 2026 Becton Dickinson has a market cap of $55.63 Billion USD. This makes Becton Dickinson the world's 422th most valuable company according to our data.\n\n**Key Financial Metrics**:\n- Market Cap · 55.54B · Enterprise Value · 74.07B · Trailing P/E · 33.49 · Forward P/E · 13.02\n- The stock trades at a price-to-earnings (P/E) ratio of 34.86 and offers a dividend yield of 2.1%.\n- The stock's 52-week range extends from a low of $162.29 to a high of $251.99.\n\n## 3. Existing Products/Services\n\nBD operates through several key segments offering diverse healthcare solutions:\n\n**BD Medical Segment**: The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. BD Medical (think syringes, needles, and devices that keep hospitals humming)\n\n**BD Life Sciences Segment**: The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers.\n\n**BD Interventional Segment**: The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business.\n\nOfferings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.\n\n## 4. Planned Products/Services/Projects\n\n**New FDA Approvals (January 2026)**: BD (NYSE: BDX) received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System on January 15, 2026. The system is expected to enter the market in early 2026, expanding BD's breast health portfolio to support earlier detection and diagnosis.\n\n**Major Investment in Prefillable Syringes**: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. BD is investing $100 million to establish BD Neopak™ Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026.\n\n**Clinical Trials**: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.\n\n## 5. Growth Strategy\n\nBD's growth strategy is centered around the **BD 2025** initiative. We continue to transform our company through BD 2025, and our intention to separate Biosciences and Diagnostic Solutions builds on the strong foundation and momentum of our strategy. The relationship strategy centers on deep integration, especially as the company executes its BD 2025 strategy focused on 'smart connected care'.\n\nKey strategic pillars include:\n- Reshaping the innovation pipeline to focus on investments in products and solutions with higher growth and higher margins, including a continued focus on tuck-in M&A.\n- Expanding simplification programs to increase margins to above pre-pandemic levels.\n\n## 6. Current and Potential Major Clients\n\nBD's customer base spans multiple segments:\n\nHospitals and Integrated Delivery Networks (IDNs) globally. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.\n\nBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.\n\nThe company has over 50 plus GLP-1 biosimilar partnerships and Becton, Dickinson and Company is winning about 80% of new biologic drugs that end up in BD devices.\n\n## 7. Financial Data & Performance\n\n**Recent Q1 2025 Financial Results** (ended December 31, 2024):\n\n- **Revenue Growth**: Revenue Growth: 9.6% total growth, 3.9% organic growth.\n- **Margin Expansion**: Adjusted Gross Margin Expansion: 370 basis points increase. Adjusted Operating Margin Expansion: 340 basis points increase.\n- **Earnings**: Adjusted Diluted EPS: $3.43, representing 28% growth.\n- **Cash Flow**: Free Cash Flow: Approximately $600 million.\n- **Guidance**: Fiscal 2025 Revenue Guidance: $21.7 billion to $21.9 billion. Fiscal 2025 Adjusted EPS Guidance: $14.30 to $14.60, reflecting 10% growth at the midpoint.\n\n**Full Year Performance**: The overall scale of Becton, Dickinson and Company's business in Fiscal Year 2025 was substantial, with total revenue reaching $21.8 billion, representing an 8.2% increase as reported over the prior year, with organic growth at 2.9%.\n\n## 8. Headwinds & Tailwinds\n\n**Tailwinds**:\n- Strong position in biologics with winning about 80% of new biologic drugs that end up in BD devices\n- The company is making significant progress in its innovation pipeline, including advancements in connected care and advanced patient monitoring.\n- Growing demand for GLP-1 drugs driving prefillable syringe demand\n\n**Headwinds**:\n- There are ongoing market dynamics in China and Biosciences research funding levels that BDX continues to monitor, which could affect future performance.\n- The company is dealing with potential tariff impacts from recent US-China and US-Mexico trade tensions, which could affect manufacturing and operational costs.\n- BDX faces challenges from translational currency impacts, which are expected to be a headwind to revenue of approximately $250 million for the full fiscal year.\n\n## 9. Market Shares\n\nBD maintains strong market positions across multiple segments:\n\n- As of 2021, the leading medical technology company based on market share was Medtronic (U.S.). At that time Medtronic held 5.8 percent of the overall medical technology market. BD ranks as one of the major players in the sector\n- The Medical Systems unit holds the number one market positions worldwide in hypodermic needles and syringes, insulin delivery syringes, I.V. catheters, and prefillable drug delivery systems.\n- The company has a strong presence in flow cytometry and diagnostics markets\n\n## 10. Comparison to Competitors\n\n**Key Competitors**: BD top competitors include: Boston Scientific, Abbott, Medtronic, Baxter International\n\n**Competitive Position**:\n- Abbott Laboratories stands as the largest competitor of Medtronic, with an impressive annual revenue of approximately $43 billion. In comparison, BD had revenues of approximately $21.8 billion in FY2025\n- Strong revenue growth in diagnostics and a balanced global presence make Abbott a consistent competitor across multiple MedTech categories.\n- BD differentiates through its comprehensive portfolio and global reach in essential medical devices\n\n## 11. Partnerships, Mergers and Acquisitions\n\n**Major Divestiture Planned**: The investment thesis centers on the Q1 2026 Reverse Morris Trust transaction with Waters Corporation that will monetize Biosciences & Diagnostics Solutions businesses for $18.8 billion (~$65 per BDX share) at attractive 5.7x revenue and 25x+ profit multiples\n\nWaters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.\n\n**Transaction Details**:\n- The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, Waters shareholder approval, and satisfaction of other customary closing conditions.\n- BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness.\n\n**Recent Partnerships**:\n- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems\n- BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec\n\n## 12. Recent Developments\n\n**January 2026**: BD (NYSE: BDX) received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System on January 15, 2026.\n\n**January 2026**: BD announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery\n\n**February 2025**: Strong Q1 FY2025 earnings with revenue growth, margin expansion and earnings per share all ahead of expectations\n\n**Upcoming**: BDX announced its intention to separate its Biosciences and Diagnostic Solutions business, which is expected to unlock significant value and enhance strategic focus.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n**Investment Highlights**:\n- Strong execution of BD 2025 strategy with meaningful margin expansion\n- Leading market positions in essential medical devices with recurring revenue streams\n- Major value unlock through Waters transaction expected Q1 2026\n- Strong financial performance with 28% adjusted EPS growth in Q1 2025\n- The company returned over $1 billion to shareholders in Q1, including $300 million in dividends and a $750 million accelerated share buyback.\n\n**Key Risks**:\n- China market headwinds and research funding pressures\n- Currency translation impacts\n- Execution risk on major divestiture transaction\n\n**Analyst Consensus**: The average 12-month price target for Becton Dickinson is USD204.83333, with a high estimate of USD270 and a low estimate of USD183. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy.\n\n**Fair Value Assessment**: Based on the comprehensive analysis, considering:\n- Current market cap of ~$55.6B\n- Strong operational execution and margin expansion\n- Value unlock from Waters transaction (~$65/share)\n- Leadership positions in growing markets (biologics, GLP-1 drugs)\n- Forward P/E of 13.02x appears reasonable for growth profile\n\n**Buy Rating**: **7.2/10**\n\n**Estimated Fair Value**: **$240-260 per share**\n\nThis fair value estimate reflects the company's strong operational fundamentals, successful execution of its BD 2025 strategy, upcoming value unlock from the Waters transaction, and leadership positions in growing healthcare markets, while accounting for near-term headwinds from China and currency impacts.",
  "generated_date": "2026-01-16T08:35:40.007754",
  "next_refresh_date": "2026-04-17T08:35:40.007754",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.42409665,
  "tokens": {
    "input": 196,
    "output": 4619,
    "cache_creation": 73281,
    "cache_read": 264733
  },
  "tldr_summary": "Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic products across healthcare, research, and pharmaceutical industries.\n\nBDX operates through three core segments: Medical, Life Sciences, and Interventional, with a strong market position in medical devices like syringes, needles, and diagnostic systems. The company is executing its BD 2025 strategy, focusing on innovation and margin expansion, and has a significant upcoming transaction to divest its Biosciences and Diagnostic Solutions business to Waters Corporation for $18.8 billion. Key growth drivers include expanding prefillable syringe production, leadership in biologics delivery (winning 80% of new biologic drug device contracts), and strong positioning in emerging markets like GLP-1 drug delivery.\n\nWith a Buy rating of 7.2/10 and an estimated fair value of $240-260 per share, BDX offers compelling investment potential driven by strategic transformation and robust market positioning in healthcare technologies."
}